Form 4 Clover Health Investments Corp: Joseph Clay Thornton (CFO) For: 16 November By Investing.com
This article reports on a Form 4 filing for Clover Health Investments Corp, indicating activity by Chief Financial Officer Joseph Clay Thornton on November 16. It primarily serves as a brief announcement of the filing without providing further details on the transaction itself. The article was published on Investing.com.
Form 144 Clover Health Investments For: 16 November By Investing.com
Investing.com reported on Form 144 for Clover Health Investments, specifically noting transactions for November 16. The brief article mentions Clover Health Investments (CLOV) with a minor percentage change and includes a Reuters copyright. The primary content of the article is a simple announcement of the Form 144 filing.
Jamie Reynoso, Clover Health CEO, sells $17,931 in stock
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (NASDAQ:CLOV), sold 4,066 shares of the company’s Class A Common Stock for a total of $17,931 on October 19, 2026. The shares were sold under a Rule 10b5-1 trading plan adopted in March 2026. This transaction follows Clover Health exceeding Wall Street's Q2 2026 expectations and raising its full-year outlook.
Clover Health Investments, Corp. Insider Sold Shares Worth $290,984, According to a Recent SEC Filing
Andrew Toy, Director and CEO of Clover Health Investments, Corp., sold 62,176 shares of the company's stock on October 15, 2026, totaling $290,984. This transaction was disclosed in a recent SEC filing. The full details of this MT Newswires article require a premium subscription.
Clover Health chief legal officer Karen Soares sells $89,821 in shares
Karen Soares, Chief Legal Officer at Clover Health Investments Corp. (NASDAQ:CLOV), sold 19,275 shares for approximately $89,821 on October 20, 2026. This sale was pre-arranged through a 10b5-1 trading plan, occurring after Clover Health's stock surged significantly year-to-date and over the past six months. Despite the sale, Soares still directly holds over 1.5 million shares, and the company recently exceeded Q2 2026 earnings expectations and raised its full-year outlook.
Clover Health CEO Karen Soares sells $68,669 in company stock By Investing.com
Clover Health's Chief Legal Officer, Karen Soares, sold 14,673 shares of Class A Common Stock worth approximately $68,669 on October 15, 2026. This transaction was identified as a "sell to cover" sale to meet tax withholding obligations from restricted stock units, not a discretionary trade. The company recently reported strong Q2 2026 financial results, exceeding Wall Street expectations with increased revenue and earnings per share.
Medicare Advantage CEO sells 4,066 Clover Health (CLOV) shares under a trading plan.
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (CLOV), sold 4,066 shares of Class A Common Stock on October 19, 2026. The shares were sold at a weighted average price of $4.41 per share through multiple transactions under a Rule 10b5-1 trading plan. After the sale, Reynoso directly held 2,770,351 shares of the company.
Clover Health CEO Karen Soares sells $68,669 in company stock
Karen Soares, Chief Legal Officer at Clover Health Investments, sold 14,673 shares of the company's Class A Common Stock for approximately $68,669 on October 15, 2026. This transaction was identified as a "sell to cover" sale to satisfy tax withholding obligations related to restricted stock units, not a discretionary trade. Following the sale, Ms. Soares beneficially owns 1,592,698 shares.
Clover Health CEO Karen Soares sells $68,669 in company stock
Karen Soares, Chief Legal Officer at Clover Health Investments Corp., sold 14,673 shares of Class A Common Stock worth approximately $68,669 on October 15, 2026. This "sell to cover" transaction was to satisfy tax withholding obligations related to the quarterly vesting of restricted stock units and was not a discretionary trade. Following the sale, Soares beneficially owns 1,592,698 shares.
Clover Health tops Medicare Advantage ratings in NJ, GA, and SC for 2027, excelling in care continuity and prevention.
Clover Health has received top ratings in U.S. News & World Report's 2027 Medicare Advantage ratings for New Jersey, Georgia, and South Carolina, excelling in care continuity, overall quality, and screening & prevention. This recognition highlights Clover's commitment to preventive care and strong physician relationships, supported by its technology platform. The company's stock (CLOV) was trading at USD 4.45, down 0.67%, following the announcement.
To cover vesting taxes, Clover Health (CLOV) CEO sells 62,176 shares.
Clover Health Investments, Corp. (CLOV) CEO Andrew Toy sold 62,176 Class A common shares on October 15, 2026, at a weighted average price of $4.68 per share. This sale was a mandatory "sell-to-cover" transaction to fund tax withholding obligations related to the quarterly vesting of restricted stock units, and not a discretionary trade. After the transaction, Toy still holds 9,078,334 shares.
Required tax withholding prompts Conrad Wai’s 23,627-share sale at Clover Health (CLOV).
Conrad Wai, CEO of Counterpart Health at Clover Health Investments, Corp. (CLOV), sold 23,627 shares of Class A common stock on October 15, 2026, at a weighted average price of $4.68 per share. This sale was a mandatory "sell to cover" transaction to meet tax withholding obligations tied to the vesting of restricted stock units, not a discretionary trade. After the transaction, Wai directly held 1,042,072 shares, with an additional 1,170,056 shares held in a family trust.
Clover Health CEO Andrew Toy sells $1.3m in shares
Clover Health CEO Andrew Toy sold 318,806 shares of Class A Common Stock worth approximately $1.3 million to cover tax withholding obligations related to the quarterly vesting of restricted stock units. These sales were not discretionary but mandated by the company's equity incentive plans. Despite the sale, Toy still beneficially owns over 9.1 million shares, and the company recently exceeded Q2 2026 earnings expectations and raised its full-year outlook.
A proposed $21K share sale would cover stock-vesting taxes for a Clover Health (CLOV) officer.
Clover Health officer Joseph Clay Thornton has proposed selling 4,487 shares of Class A common stock, valued at approximately $21,000, on October 15, 2026. This "sell to cover" transaction is intended to satisfy tax withholding obligations related to the vesting of restricted stock units. Thornton has made similar sales in July and August 2026 for the same purpose.
To cover taxes, a Clover Health (CLOV) officer proposes selling 17,858 shares valued at $83.6K.
Clover Health Investments, Corp. (CLOV) officer Jamie Reynoso plans to sell 17,858 shares of Class A common stock on October 15, 2026, valued at approximately $83,575.44. This proposed sale is a non-discretionary "sell-to-cover" transaction aimed at funding tax withholding obligations tied to the vesting and settlement of restricted stock units. The company emphasizes that this is not a discretionary transaction by the reporting person.
Tax withholding prompts a proposed 14,341-share sale by Clover Health (CLOV) officer Karen M. Soares.
Clover Health Investments, Corp. (CLOV) officer Karen M. Soares has proposed selling 14,341 shares of Class A common stock, valued at approximately $67,115.88. This non-discretionary sale, with an approximate date of October 15, 2026, is intended to cover tax withholding obligations associated with the vesting of restricted stock units. The filing also details prior sales made under a 10b5-1 plan on July 15, 2026, July 20, 2026, and September 15, 2026.
To cover taxes, Clover Health (CLOV) officer Andrew Toy proposes selling 60,765 shares.
Clover Health officer Andrew Toy has proposed selling 60,765 Class A common shares worth approximately $284,380.2 on October 15, 2026. This sale is intended to cover tax withholding obligations related to restricted stock unit vesting and is not a discretionary transaction. The filing also lists prior "sell to cover" transactions by Toy, including sales on July 15, August 10, and October 1, 2026.
To cover taxes, Clover Health (CLOV) officer Conrad Wai proposes a $110K share sale.
Clover Health Investments, Corp. (CLOV) officer Conrad Wai proposes to sell 23,463 shares of Class A common stock, valued at approximately $109,806.84, around October 15, 2026. This "sell to cover" transaction is intended to fund tax withholding obligations related to the vesting and settlement of restricted stock units and is not a discretionary sale. The filing also notes prior sales of 24,215 shares on July 15, 2026, and 300,000 shares on September 15, 2026.
Weekly Recap: 5.0/4.5 CMS 2027 star ratings and Q3 2026 results webcast
Clover Health Investments Corp. (NASDAQ:CLOV) announced that its Medicare Advantage PPO plans received 5.0 stars and its HMO plans 4.5 stars for 2027 from CMS. This higher rating is expected to allow the company to reinvest in member benefits and expand Medicare enrollment while maintaining financial stability. Clover Health is also scheduled to release its Q3 2026 results and hold a webcast on November 4, 2026.
Under a trading plan, Jamie L. Reynoso sells Clover Health (CLOV) shares at $4.63 on average.
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health (CLOV), sold 2,006 shares of Class A common stock on October 7, 2026, at a weighted average price of $4.63 per share. This sale was conducted under a Rule 10b5-1 trading plan established on March 12, 2026. Following the transaction, Reynoso directly holds 2,792,690 shares.
Clover Health Q3FY26 Results: Earnings call set for Nov 4, 2026
Clover Health will release its third-quarter 2026 financial results on November 4, 2026, after market close, followed by a conference call and webcast at 5:00 pm ET to discuss performance. The company, a physician enablement technology firm focusing on Medicare Advantage plans, uses its Clover Assistant platform to improve patient outcomes and extends its technology through Counterpart Health. A webcast of the earnings call will be archived on the company's investor relations website for 12 months.
To cover taxes, Clover Health (CLOV) CEO sells 318,806 shares at an average $4.19.
Clover Health Investments' CEO, Andrew Toy, sold 318,806 Class A shares at an average price of $4.19 per share on October 1, 2026. This sale was conducted to cover tax withholding obligations associated with the quarterly vesting of restricted stock units and was an issuer-mandated "sell to cover" transaction, not a discretionary trade. Following the transaction, Toy directly held 9,140,510 Class A shares.
An officer proposes selling 8,706 Clover Health (CLOV) shares to cover stock-award taxes.
An officer at Clover Health Investments, Corp. (CLOV), Jamie Reynoso, plans to sell 8,706 Class A common shares worth $40,744.08 around October 5, 2026. This sale is designated as a "sell-to-cover" transaction to fund tax withholding obligations related to restricted stock unit vesting, not a discretionary sale. The SEC filing provides details on the proposed sale and lists five previous similar transactions by Reynoso.
An executive sells 8,750 Clover Health (CLOV) shares in a mandatory sale to cover taxes.
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health (CLOV), sold 8,750 Class A common shares for $4.42 each on October 5, 2026. This mandatory "sell-to-cover" transaction was executed to fulfill tax withholding obligations related to the quarterly vesting of his restricted stock units. Following the sale, Reynoso directly holds 2,794,696 shares.
To cover vesting taxes, Andrew Toy proposes selling 309,558 Clover Health (CLOV) shares.
Andrew Toy, an officer at Clover Health Investments, Corp. (CLOV), plans to sell 309,558 shares of Class A Common Stock with an aggregate market value of $1,309,430.34. This proposed sale is a "sell-to-cover" transaction intended to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units, not a discretionary transaction. The filing also notes previous sales made under a 10b5-1 plan in July and August 2026.
Robert G. Torricelli Files Initial Ownership Disclosure as Clover Health Director
Robert G. Torricelli has filed an initial ownership disclosure for Clover Health Investments, Corp. (NASDAQ:CLOV) following his appointment as a director. The filing indicates he beneficially owns 174,416 shares, comprising 141,253 directly held Class A Common Stock shares and 33,163 shares underlying restricted stock units that vest in April 2027. This disclosure was made public on October 1, 2026, with the triggering event of his directorship occurring on September 22, 2026.
Total common shares outstanding of Clover Health Investments Corp. Class A – HAN:7QD
The article focuses on the total common shares outstanding for Clover Health Investments Corp. Class A, traded under the symbol HAN:7QD on the Hannover Stock Exchange. It provides a static snapshot of this financial metric and indicates that the information is "Made by humans."
Form 8K Clover Health Investments Corp For: 25 September By Investing.com
This article announces that Clover Health Investments Corp filed a Form 8K on September 25. The filing is a standard disclosure for material events that shareholders should know about, often indicating significant corporate actions or changes. The brief notice from Investing.com highlights this regulatory update for investors tracking the company.
Form 8K Clover Health Investments Corp For: 25 September By Investing.com
This article announces that Clover Health Investments Corp. filed a Form 8K on September 25. The publication by Investing.com provides no further details beyond this announcement and includes general market data and news headlines not related to the filing itself.
Form 8K Clover Health Investments Corp For: 25 September By Investing.com
This article announces that Clover Health Investments Corp. filed a Form 8K on September 25. The brief report from Investing.com includes the stock symbol CLOV, which experienced a slight decrease of 0.44%.
Clover Health Investments, Corp. (CLOV) Stock Price, News, Quote & History
This page provides detailed financial information for Clover Health Investments, Corp. (CLOV), including its current stock price, historical data, and key statistics. It presents a summary of the company's market performance, valuation measures, profitability, and balance sheet information, along with recent news and research reports. The page also includes a chart for visualizing stock trends and offers various financial metrics for analysis.
Clover Health (NASDAQ: CLOV) exec plans stock sale to cover taxes
Joseph Frank Oldakowski, an officer at Clover Health Investments, Corp. (CLOV), has filed a notice to sell 3,170 shares of Class A Common Stock. This transaction, executed under Rule 144, is a "sell to cover" to satisfy tax withholding obligations related to vested restricted stock units and is not a discretionary sale. Oldakowski has made previous sales in the last three months, including 12,102 shares and 20,000 shares on separate occasions.
Clover Health (CLOV) officer plans tax-withholding share sale
An officer at Clover Health (CLOV), Karen M. Soares, has filed a Form 144 indicating her intent to sell 6,416 shares of Class A common stock on September 15, 2026. This "sell to cover" transaction is primarily to satisfy tax withholding obligations arising from the vesting of restricted stock units. The proposed sale, valued at $29,898.56, is not considered a discretionary trade but rather a routine transaction for tax purposes.
Clover Health (CLOV) exec sells 1,921 shares under preset plan
Clover Health's Medicare Advantage CEO, Jamie L. Reynoso, sold 1,921 shares of Class A Common Stock on September 17, 2026, for $4.56 per share, under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Reynoso still directly holds 2,803,446 shares of CLOV. The sale, valued at approximately $9,000, was reported in a Form 4 SEC filing.
Clover Health (NASDAQ: CLOV) exec sale is tax-driven
Clover Health's VP of Finance and Controller, Joseph Frank Oldakowski, sold 3,170 shares of Class A Common Stock at $4.64 per share on September 16, 2026. This transaction was not a discretionary trade but a mandatory "sell to cover" to satisfy tax withholding obligations from the vesting of restricted stock units (RSUs). After the sale, Oldakowski directly holds 275,897 shares, and the remaining RSUs will vest quarterly until June 2029.
Clover Health (NASDAQ: CLOV) Medicare chief sells 9,273 shares to cover RSU taxes
Clover Health's Medicare Advantage CEO, Jamie L. Reynoso, sold 9,273 Class A shares at a weighted average price of $4.78 per share on September 15, 2026. This sale was a mandatory "sell to cover" transaction to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) and was not a discretionary trade. Following the sale, Reynoso directly holds 2,805,367 shares of Class A Common Stock.
Clover Health (CLOV) insider sells 300,000 shares in pre-set plan
Clover Health officer Wai Conrad sold 300,000 Class A shares for approximately $1.42 million under a pre-set Rule 10b5-1 plan. The sale occurred on September 15, 2026, at a weighted average price of $4.72 per share. Following the transaction, Conrad continues to hold over 2.2 million shares, both directly and through a family trust.
Clover Health CEO, Medicare advantage, Jamie Reynoso sells $44,324 in CLOV shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (NASDAQ:CLOV), sold 9,273 shares of the company's Class A Common Stock for $44,324 on September 15, 2026, to cover tax withholding obligations from vested restricted stock units. This sale occurred after Clover Health's stock surged 137% in six months and despite the stock currently being considered overvalued by InvestingPro. The company recently exceeded Q2 2026 earnings and revenue expectations, and raised its full-year outlook.
Clover Health CFO Karen Soares sells $32,723 in stock
Clover Health CFO Karen Soares sold 6,846 shares of Class A Common Stock for $32,723 on September 15, 2026. This "sell to cover" transaction was to meet tax withholding obligations related to the vesting of restricted stock units. The sale occurred amidst a 137% surge in Clover Health shares over six months and a recent strong Q2 2026 earnings report that exceeded analyst expectations.
Clover Health CFO Karen Soares sells $32,723 in stock By Investing.com
Clover Health CFO Karen Soares sold 6,846 shares of Class A Common Stock for $32,723 on September 15, 2026, to cover tax withholding obligations from vested restricted stock units. This "sell to cover" transaction is not a discretionary trade. The sale occurred as Clover Health's shares have surged, and the company recently exceeded Q2 2026 earnings and revenue expectations.
Clover Health (CLOV) investor plans tax sell-to-cover trade
A Clover Health (CLOV) stockholder, Jamie Reynoso, plans to sell 8,691 shares of Class A common stock valued at $40,500.06 through Morgan Stanley Smith Barney LLC. This sale is a "sell to cover" transaction to fulfill tax withholding obligations upon the vesting of restricted stock units, not a voluntary reduction in investment. The filing also notes previous 10b5-1 plan sales by Reynoso in the past three months.
Clover Health VP of finance and controller sells $103,200 in stock
Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health Investments, Corp., sold 20,000 shares of the company’s Class A Common Stock for $103,200 on September 14, 2026. This sale occurred after CLOV stock surged significantly year-to-date and in the prior week. Despite the sale, Oldakowski still directly holds 279,067 shares, and the company recently reported strong Q2 2026 financial results, exceeding Wall Street expectations.
Clover Health to Participate in Upcoming Investor Conferences
Clover Health Investments, Corp. announced its participation in two upcoming investor conferences in September 2026. Interim Chief Financial Officer, Clay Thornton, will present at the Jefferies Healthcare Services and Technology Conference and also participate in the Deutsche Bank Healthcare Summit. The company is a physician enablement technology firm focused on improving healthcare access and outcomes for Medicare beneficiaries through its Clover Assistant platform.
Clover Health Investments Corp. Class A (CLOV) Peer Comparison – Compare with Others
This article provides a detailed financial peer comparison for Clover Health Investments Corp. Class A (CLOV) against other healthcare companies like Fresenius Medical Care, Progyny, Alignment Healthcare, and UnitedHealth Group. It includes key financial metrics such as market cap, revenue, net profit, various ratios (P/E, P/B, RoE, ROCE, growth, solvency), and income statement, liabilities, assets, and cashflow data. The comparison highlights CLOV's current market position and financial performance relative to its industry peers.
Clover Health interim CFO Thornton sells $78,032 in shares By Investing.com
Joseph Clay Thornton, interim CFO of Clover Health Investments Corp., sold 17,775 shares valued at $78,032. These sales were not discretionary but were "sell to cover" transactions to meet tax withholding obligations from vesting restricted stock units (RSUs). The company has recently reported strong Q2 2026 financial results, exceeding Wall Street expectations, and raised its full-year outlook.
Clover Health (NASDAQ: CLOV) CFO’s tax sale covers RSU vesting
Clover Health's Interim CFO, Joseph Clay, sold 17,775 shares of Class A Common Stock at a weighted average price of $4.39 per share on August 17, 2026. This transaction was a non-discretionary "sell to cover" to satisfy tax obligations related to the vesting of 6.25% of his restricted stock units (RSUs). After the sale, Clay directly holds 1,249,526 shares, and his remaining RSUs will continue to vest quarterly through February 2028.
Clover Health interim CFO Thornton sells $78,032 in shares
Joseph Clay Thornton, interim CFO of Clover Health Investments, sold 17,775 shares of the company's Class A Common Stock for $78,032. These sales were not discretionary but rather "sell to cover" transactions to meet tax withholding obligations from vesting restricted stock units (RSUs). Following the transactions, Thornton beneficially owns 1,249,526 shares.
Clover Health (NASDAQ: CLOV) notes $21K 10b5-1 sale by Thornton
Clover Health Investments Corp. (NASDAQ: CLOV) filed a Form 144, indicating a planned transaction involving 16,942 Class A shares linked to restricted stock units granted on August 16, 2026. The filing also disclosed a prior 10b5-1 Plan Sale by Joseph Clay Thornton on July 15, 2026, where 4,630 Class A shares were sold for $21,622.10. The shares for the planned transaction are held through Morgan Stanley Smith Barney LLC.
Clover Health interim CFO Thornton sells $78,032 in shares
Joseph Clay Thornton, interim CFO of Clover Health Investments Corp., sold 17,775 shares for $78,032 on August 17, 2026, at a weighted average price of $4.39. These shares were sold to cover tax withholding obligations tied to restricted stock unit vesting, not as discretionary trades. Following the sale, Mr. Thornton directly owns 1,249,526 shares of Class A Common Stock.
Clover Health Interim CFO Joseph Clay Thornton Awarded 54,347 RSUs with Four-Year Vesting
Clover Health's Interim CFO, Joseph Clay Thornton, was granted 54,347 Restricted Stock Units (RSUs) of Class A Common Stock. These RSUs, valued at $0, will vest over a four-year period, with 25% vesting on August 12, 2027, and the remainder in quarterly installments, fully vesting by August 12, 2030. This grant increases Thornton's direct beneficial ownership to 1,267,301 shares of Class A Common Stock, contingent upon his continued service.